Journal profile · Endocrinology & Metabolism
Growth Hormone & IGF Research
ISSN 1096-6374 · eISSN 1532-2238 · Elsevier Ltd · ENGLAND · Bimonthly
Growth Hormone & IGF Research: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.97; hybrid open access; APC about USD 3,570; median 82 days to acceptance (47 articles, last 24 months); community-reported acceptance: fairly easy; 20 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Growth Hormone & IGF Research is published by Elsevier Ltd and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Growth Hormone and Insulin-like Growth Factors, Pituitary Gland Disorders and Treatments and Metabolism, Diabetes, and Cancer, together about 51.6% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Growth Hormone & IGF Research is a forum for research on the regulation of growth and metabolism in humans, animals, tissues and cells. It publishes articles on all aspects of growth-promoting and growth-inhibiting hormones and factors, with particular emphasis on insulin-like growth factors (IGFs) and growth hormone. This reflects the increasing importance of growth hormone and IGFs in clinical medicine and in the treatment of diseases.
From the journal's Aims & Scope
Research area (LetPub): Endocrinology & Metabolism
Editor-in-chief K. YuenPublisher website
Editorial board by country: none in mainland China; most named United States 19, Germany 6, Australia 5, Denmark 5, United Kingdom 4 (56 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Growth Hormone and Insulin-like Growth FactorsMedicine38.8%
- Pituitary Gland Disorders and TreatmentsMedicine7.9%
- Metabolism, Diabetes, and CancerBiochemistry, Genetics and Molecular Biology4.9%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology4.3%
- Diet and metabolism studiesMedicine3.4%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance3.2%
- Birth, Development, and HealthMedicine3.1%
- Human auditory perception and evaluationEngineering3.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cell Biology | Zone 4 |
| Minor | Endocrinology & Metabolism | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cell Biology | Zone 4 |
| Minor | Endocrinology & Metabolism | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cell Biology | Zone 4 |
| Minor | Endocrinology & Metabolism | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.97LetPub ·
- Impact factor (publisher)
- 2Publisher website ·
- CiteScore 2026-06
- 3.7LetPub ·
- CiteScore (publisher)
- 3.7Publisher website ·
- SJR 2026-06
- 0.63LetPub ·
- SNIP 2026-06
- 0.89LetPub ·
- h-index
- 56LetPub ·
- h-index
- 79OpenAlex ·
- i10-index
- 1,009OpenAlex ·
- 2-year mean citedness
- 1.09OpenAlex ·
- Self-citation rate
- 5%LetPub ·
- Share of gold OA articles
- 20%LetPub ·
Volume
- Articles per year
- 16LetPub ·
Articles by year OpenAlex count · 3,081 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 33 | 7 | 9 |
| 2025 | 20 | 1 | 12 |
| 2024 | 24 | 11 | 63 |
| 2023 | 20 | 8 | 105 |
| 2022 | 40 | 10 | 263 |
| 2021 | 40 | 9 | 384 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
82 daysMedian, submission to acceptance · P25–P75 36 days – 110 days
- Acceptance to online
- median 4 days (47 articles)
- Submission to online
- median 89 days
- Sample
- 47 articles with submission and acceptance dates (52 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 monthsLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 12 daysPublisher website ·
- First decision after review
- 50 daysPublisher website ·
- Submission to acceptance
- 89 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,570 / EUR 3,340 / GBP 2,860 / JPY 442,790 | — | — | |
| Publisher website | USD 3,860 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Numbered, in order of citation
- Highlights
- Required
Article types accepted7
- mini-reviewsIt is intended that these be short reviews covering recent advances and ideas in an area. They will be published regularly. There are no special requirements fo…Length not stated
- original research articleShort CommunicationsManuscripts may be submitted as short communications if they do not exceed four printed pages (inclusive of all text, tables, illustrations …Length not stated
- research paperPapers should be set out as follows, with each section beginning on a separate sheet; title page, summary, text, acknowledgments, references, tables, captions t…Length not stated
- reviewShort CommunicationsManuscripts may be submitted as short communications if they do not exceed four printed pages (inclusive of all text, tables, illustrations …Length not stated
- short communicationShort CommunicationsManuscripts may be submitted as short communications if they do not exceed four printed pages (inclusive of all text, tables, illustrations …Length not stated
- short communicationsManuscripts may be submitted as short communications if they do not exceed four printed pages (inclusive of all text, tables, illustrations and references). The…Length not stated
- short reviewShort CommunicationsManuscripts may be submitted as short communications if they do not exceed four printed pages (inclusive of all text, tables, illustrations …Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Authors must follow Elsevier's Publishing Ethics Policy. Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
Supports open access; options described on open access information page. Model summary
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process; submissions initially assessed by editors; if suitable, reviewed by a minimum of two reviewers; decision made by editors. Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed per Elsevier's article sharing policy; does not count as prior publication. Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Ltd
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- ISSN
- 1096-6374
- Electronic ISSN
- 1532-2238
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Growth Hormone & IGF Research
What CAS zone is Growth Hormone & IGF Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Growth Hormone & IGF Research is in Zone 4 of Medicine, and in Zone 4 of the minor category Cell Biology / Endocrinology & Metabolism. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Growth Hormone & IGF Research?
The latest impact factor listed by LetPub is 1.97; CiteScore 3.7, h-index 79.
How long does peer review take at Growth Hormone & IGF Research?
Based on the dates recorded on 47 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 82 days (interquartile range 36–110 days); authors report an average review time of about 12 months; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Growth Hormone & IGF Research?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Numbered, in order of citation; Highlights: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Growth Hormone & IGF Research based?
Of the 56 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (19), Germany (6) and Australia (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Growth Hormone & IGF Research?
According to LetPub and DOAJ records, Growth Hormone & IGF Research is indexed in SCIE and Scopus.
Is Growth Hormone & IGF Research open access, and what is the APC?
Growth Hormone & IGF Research is a hybrid journal. For open-access publication: APC about USD 3,570.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .